Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Bicycle Therapeutics PLC has received a consensus rating of "Moderate Buy" from ten brokerages, with three suggesting a hold and seven recommending a buy.
• Recent price target adjustments from analysts have varied significantly, with estimates ranging from $10.00 to $44.00, indicating a wide range of opinion on the stock's potential.
• The company reported a loss of $1.14 earnings per share, missing analysts' estimates, and had a revenue of $2.90 million for the quarter, far below the anticipated $9.43 million.

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $22.2222.

Several research firms have weighed in on BCYC. Morgan Stanley lowered their price target on Bicycle Therapeutics from $17.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 12th. JMP Securities reduced their price objective on Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating on the stock in a research report on Tuesday, August 12th. B. Riley reduced their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Royal Bank Of Canada set a $27.00 price objective on Bicycle Therapeutics and gave the company an "outperform" rating in a research report on Monday, August 11th. Finally, Oppenheimer reiterated an "outperform" rating and set a $44.00 price objective (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors have recently modified their holdings of BCYC. Barclays PLC increased its position in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares during the last quarter. Jane Street Group LLC increased its position in shares of Bicycle Therapeutics by 18.9% during the 4th quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock valued at $336,000 after purchasing an additional 3,811 shares during the last quarter. Bank of America Corp DE increased its position in shares of Bicycle Therapeutics by 2.1% during the 4th quarter. Bank of America Corp DE now owns 392,859 shares of the company's stock valued at $5,500,000 after purchasing an additional 7,994 shares during the last quarter. Baker BROS. Advisors LP grew its position in Bicycle Therapeutics by 15.8% during the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock worth $152,395,000 after acquiring an additional 1,485,397 shares during the last quarter. Finally, Caption Management LLC bought a new position in Bicycle Therapeutics during the 4th quarter worth approximately $2,283,000. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC traded up $0.08 on Friday, hitting $7.08. The company's stock had a trading volume of 110,884 shares, compared to its average volume of 259,974. The company has a 50-day simple moving average of $7.66 and a 200 day simple moving average of $8.49. Bicycle Therapeutics has a 1 year low of $6.10 and a 1 year high of $28.67. The company has a market capitalization of $490.29 million, a PE ratio of -2.02 and a beta of 1.44.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%. The business had revenue of $2.90 million during the quarter, compared to analysts' expectations of $9.43 million. On average, equities research analysts expect that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.